RhD haemolytic disease of the fetus and the newborn

Blood Reviews

Volumn 14, Issue 1, 2000, Pages 44-61

  Urbaniak, S J ^a   Greiss, M A ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NE Scotland Regional Transfusion Centre ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY; RHESUS D ANTIGEN;

ALLOIMMUNIZATION; AMNIOCENTESIS; ANEMIA; ERYTHROCYTE; EXCHANGE BLOOD TRANSFUSION; FEMALE; FETUS; FETUS BLOOD SAMPLING; FETUS HYDROPS; FETUS MORTALITY; GENOTYPE; HUMAN; INTRAUTERINE BLOOD TRANSFUSION; MORBIDITY; MOTHER; NEWBORN; NEWBORN HEMOLYTIC DISEASE; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; STILLBIRTH;

EID: 0034007375     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.1999.0123     Document Type: Review

References (116)

1. Bowman J. M. The prevention of Rh immunization. Trans Med Rev. 2:1988;129-150.
2. Diamond L. K., Blackfan K. D., Baty J. M. Erythroblastosis fetalis and its association with universal edema of the fetus, icterus gravis neonatorum and anemia of the newborn. J Pediatr. 1:1932;269-309.
3. Hawksley J. C., Lightwood R. A contribution to the study of erythroblastosis: icterus gravis neonatorum. Quart J Med. 3:1934;155-209.
4. Gilmour J. R. Erythroblastosis fetalis. Arch Dis Child. 19:1944;1-25.
5. Darrow R. R. Icterus gravis (erythroblastosis neonatorum, examination of etiologic considerations). Arch Pathol. 25:1938;378-417.
6. Levine P., Stetson R. E. An unusual case of intra-group agglutination. J Amer Med Ass. 113:1939;126-127.
7. Landsteiner K., Wiener A. S. An agglutinable factor in human blood recognized by immune sera for rhesus blood. Proc Soc Exp Biol Med. 43:1940;223.
8. Chown B. Anemia from bleeding of the fetus into the mother’s circulation. Lancet. 1:1954;1213-1215.
9. BMJ. 2:1966;904-907.
10. Pollack W., Gorman J. G., Freda V. J. Results of clinical trials of RhoGAM in women. Transfusion. 8:1968;151.
11. Technical Report Series. 1971;468.
12. Proceedings of the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti-D Prophylaxis. Urbaniak, S. J, Br J Obstet Gynaecol, 1998, 105 suppl 18.
13. Anderson K. C., Ness P. M. Scientific Basis of Transfusion Medicine. Implication for Clinical Practice. 2000.
14. Garratty, G. Immunobiology of Transfusion Medicine. Marcel Dekker, 1994.
15. Issitt P. D., Anstee D. J. Applied Blood Group Serology. 1998;Montgomery Scientific Publications.
16. Bowman J. M. The management of Rh-isoimmunisation. J Obstet Gynaecol. 52:1978;1-16.
17. Bowman J. M. Treatment options for the fetus with alloimmune hemolytic disease. Trans Med Rev. 4:1990;191-207.
18. Mollison, P. L. Engelfriet, C. P. Contreras, M. Blood Transfusion in Clinical Medicine, 10th ed, Chapters 3, 5, 12. Oxford, Blackwell Scientific Publications, 1997.
19. Murphy K. W., Whitfield C. R. Rhesus disease in this decade. obstetrics. Contemp. Rev. Obstet. Gynaecol. 6:1994;61-67.
20. Tannirandorn Y., Rodeck C. H. New Approach in the Treatment of Haemolytic Disease of the Fetus. Contreras Marcela. Blood Transfusion: The Impact of New Technologies. Bailliere’s Clinical Haematology Series, 1990;289-320 Bailliere, London.
21. White C. A., Goplerud C. P., Kisker C. T. Intrauterine fetal transfusion, 1965-1976, with an assessment of the surviving children. Am J Obstet Gynecol. 130:1978;933-942.
22. Stites, D. P. Tern, A. I. Parslow, T. G. Basic & Clinical Immunology 8th ed. A LANGE Medical Book.
23. null. Blood. 36:1970;310.
24. nullred blood cells. Blood. 48:1976;457-468.
25. nullhuman erythrocytes have an abnormal member phospholipid organisation. Biochem J. 221:1984;931-934.
26. Singleton B. K., Green C. A., Avent N. D. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense muatation in Africans with the RhD-negative blood group phenotype. Blood. 95:2000;12-18.
27. Scott M. L., Voak D., Jones J. W. A model for RhD - the relationship of 30 serologically defined epitopes to predicted structure. Biotest Bulletin. 5:1997;459-466.
28. Daniels, G. Lomas-Francis, C. Wallace, M. Epitopes of RhD: Serology and Molecular Genetics. Molecular and Functional Aspects of Blood Groups Antigens. Silberstein, L. E. American Association of Blood Banks, Bethesda, Maryland, 1995, 193, 228.
29. Vengelen-Tyler, V. Technical Manual, American Association of Blood Banks, 1999.
30. Avent N. D., Reid M. E. The Rh group system: a review. Blood. 95:2000;375-387.
31. Wagner F. F., Gassner C., Muller D. S. Molecular basis of weak D phenotypes. Blood. 93:1999;385-393.
32. Lee D., Contreras M., Robson S. C. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. Transfusion Medicine. 9:1999;93-97.
33. Pollack W., Ascari W. Q., Kochesky R. J. Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion. 11:1971;333-339.
34. Urbaniak S. J., Robertson A. G. A successful programme of immunising Rh-negative male volunteers for anti-D production using thawed blood. Transfusion. 21:1981;64-69.
35. Jakobowicz R., Williams L., Silberman F. Immunisation of Rh-negative volunteers by repeated injection of very small amounts of Rh-positive blood. Vox Sang. 23:1972;376-381.
36. Voak D., Cann R., Finney R. D. Guideline for administration of Blood products: transfusion of infants and neonates. Transfusion Medicine. 4:1994;63-69.
37. Napier J. A. F., Chapman J. F., Forman K. Guideline for pre-transfusion compatibility procedures in blood transfusion laboratories. Transfusion Medicine. 6:1996;273-283.
38. Urbaniak S. J., Stott L. M., Wilson D. W. The identification of peptides which stimulate helper T-cells in vitro. Transfusion. 39:1999;1S.
39. Bowman J. M., Pollock J. M., Penston L. E. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 51:1986;117-121.
40. Hann, I. M. Gibson, B. E. S. Letsky, E. A. Fetal and Neonatal Haematology (Chapters 5 & 7). Bailliere Tindall, 1991.
41. Quinley, E. D. Immunohaematology: Principles and Practice. J B Lippincott Company, 1993.
42. Engelfriet C. P., Ouwehand W. H. ADCC and Other Cellular Bioassays for Predicting the Clinical Significance of Red Cell Alloantibodies. Contreras M. Blood Transfusion: The Impact of New Technologies, Bailliere’s Clinical Haematology Series, 1990;321-337 Bailliere, London.
43. Urbaniak S. J. ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus antibodies II. Investigation into mechanism of lysis. Br J Haematol. 42:1979;315-328.
44. Urbaniak S. J., Greiss M. A. ADCC (K-cell) lysis of human erythrocytes sensitised with rhesus antibodies III. Comparison of IgG anti-D agglutinating and lytic (ADCC) activity and the role of IgG subclasses. Br J Haematol. 46:1980;447-453.
45. Schofield D., Cotran R. S. Diseases of Infancy and Childhood. Cotran R. S., Kumar V., Collins T. Robbins Pathologic Basis of Disease. Chapter 11. 1999;W B Saunders Company.
46. Mollison, P. L. Blood transfusion in clinical medicine, 1961, 614.
47. Dacie J. V. Haemolytic disease of the newborn. Haemolytic Anaemia, 3rd. 1999;Churchill Livingstone.
48. Naiman J. L. Erythroblastosis fetalis. Oski F. A., Naiman J. L. Hematologic problems in the newborn. 1982;283-346 WB Saunders, Philadelphia.
49. Koenig J. M., Christensen R. D. Neutropenia and thrombocytopenia in infants with Rh hemolytic disease. J Pediatr. 114:1989;625-631.
50. Koenig J. M., Ashton R. D., De V. G., Christensen R. D. Late hyporegenerative anemia in Rh hemolytic disease. J Pediatr. 115:1989;315-318.
51. Thorp J. A., O'Connor T., Callenbach J. Hyporegenerative anemia associated with intrauterine transfusion in rhesus hemolytic disease. Am J Obstet Gynecol. 165:1991;79-81.
52. Ohls R. K., Wirkus P. E., Christensen R. D. Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease. Pediatrics. 90:1992;678-680.
53. Koenig J. M. Evaluation and treatment of erythroblastosis fetalis in the neonate. Christensen R. D. Hematologic problems of the neonate. 2000;185-207 WB Saunders, Philadelphia.
54. Zipursky A., Chintu C., Brown E. The quantification of spherocytes in ABO hemolytic disease. J Pediatr. 94:1979;965-967.
55. Bowman J. M. Immune hemolytic disease. Nathan D. G. Hematology of infancy and childhood. 1997;53-78 WB Saunders, Philadelphia.
56. Dunn P. M. Obstructive jaundice and haemolytic disease of the newborn. Arch Dis Child, 38:1963;54.
57. Phibbs R. H., Johnson P., Tooley W. H. Cardiorespiratory status of erythroblastotic newborn infants. II. Blood volume, hematocrit, and serum albumin concentration in relation to hydrops fetalis. Pediatrics. 53:1974;13.
58. Volpe J. J. Bilirubin and brain injury. Volpe J. J. Neurology of the newborn. 1987;386-408 WB Saunders, Philadelphia.
59. Harris L. E., Farrell F. J., Shorter R. G. Conjugated serum bilirubin in erythroblastosis fetalis: an analysis of 38 cases. Mayo Clin Proc. 37:1962;574.
60. Shenker S., Dawber N. H., Schmid R. Bilirubin metabolism in the fetus. J Clin Invest. 43:1964;32.
61. Margulies M., Voto L. S., Mathet E. High does intravenous IgG for the treatment of severe rhesus alloimmunisation. Vox Sang. 61:1991;181-189.
62. Urbaniak S. J., Duncan J. I., Armstrong-Fisher S. S. Transfer of anti-D antibodies across the isolated perfused human lobule and inhibition by high dose intravenous immunoglobulin: a possible mechanism of action. Br J Haematol, 96:1997;186-193.
63. Voto L. S., Sexer H., Ferreiro G. Neonatal administration of high-dose intravenous immunoglobulin in rhesus hemolytic diease. J Perinat Med. 23:1995;443-451.
64. Moise K. J. Changing trends in the management of red blood cell alloimmunization in pregnancy. Arch Pathol Lab Med. 118:1994;421-428.
65. Voak D., Mitchell R., Bowell P. Guidelines for blood grouping and red cell antibody testing during pregnancy. Transfusion Medicine. 6:1996;71-74.
66. Sebring, E. S. Fetomaternal Hemorrhage - Incidence and Method of Detection and Quantitation. Hemolytic Disease of the Newborn. G. Garratty, American Association of Blood Banks, 1984, 87, 117.
67. Van den Veyver I., Saade G., Lockett L. The use of Kleihauer-Betke stain in pregnant patients with abdominal trauma. Am J Obstet Gynecol. 168:1993;432.
68. Kelsey P., Reilly J. T., Chapman J. F. The estimation of fetomaternal haemorrhage. Transfusion Medicine. 9:1999;87-92.
69. Clark D., Greiss M. A., Urbaniak S. J. A prospective study of routine antenatal enzyme antibody screening demonstrates lack of clinical value in predicting haemolytic disease of the newborn. Br J Haematol. 106:1999;824-826.
70. Bruce M., Chapman J. F., Duguid J. Addendum for guidelines for blood grouping and red cell antibody testing during pregnancy. Transfusion Medicine. 9:1999;99.
71. Clark A. C. Red-cell antibodies in pregnancy: evidence overturned. Lancet. 347:1996;485-486.
72. Urbaniak S. J., Greiss M. A., Crawford R. J. Prediction of the outcome of rhesus disease of the newborn: additional information using an ADCC assay. Vox Sang. 46:1984;323-329.
73. Hadley A. G., Wilkes A., Goodrick J. The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn. Br J Obstet Gynaecol. 105:1998;231-234.
74. Iskaros J., Kingdom J., Morrison J. J. Prospective non-invasive monitoring of pregnancies complicated by red cell alloimmunization. Ultrasound Obstet Gynaecol. 11:1998;432-437.
75. Mari G. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia dut to maternal red-cell alloimmunization. N Engl J Med. 342:2000;9-14.
76. Liley A. W. Liquor amnii analysis in management of pregnancy complicated by rhesus immunisation. Am J Obstet Gynecol. 82:1961;1359.
77. Queenan J. T., Tomai T. P., Ural S. H. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks gestation: a proposal for clinical management. Am J Obstet Gynecol. 168:1993;1370-1376.
78. Whitfield C. R. A three year assessment of an Action Line method of timing intervention in rhesus isoimmunisation. Am J Obstet Gynecol. 108:1970;1239-1244.
79. Bennett P. R., Le Van Kim C., Colin Y. Prenatal determination of fetal RhD type by DNA amplification. N Engl J Med. 329:1993;607-610.
80. Simsek S., Blecker P. M. M., Von dem Borne A. E. G. Kr. Prenatal determination of fetal RhD type. N Engl J Med, 330:1994;795.
81. Simsek S., Faas B. H. W., Blecker P. M. M. Rapid RhD genotyping by polymerase chain reaction-based amplification of DNA. Blood. 85:1995;2975-2980.
82. Gussner C., Schmarda A., Kilger-Nogler B. RhD/CE typing by polymerase chain reaction using sequence-specific primers. Transfusion. 37:1997;1020-1026.
83. Hessner M. J., McFarland J. C., Eindeen D. J. Genotyping of KEL1 and KEL2 of the human Kell blood group system by PCR-SSP. Transfusion. 36:1996;495-499.
84. Lighten A. D., Overton T. G., Sepulveda W. Accuracy of prenatal determination of RhD type status by polymerase chain reaction with amniotic cells. Am J Obstet Gynecol. 173:1995;1182-1185.
85. u), and partial D phenotypes as determined by multiplex polymerase chain analysis of the RHD gene. Blood. 89:1997;2568-2577.
86. Okuda H., Kawano M., Iwamoto S. The RHD gene is highly detectable in RHD-negative Japanese donors. J Clin Invest. 100:1997;373-379.
87. Crombach G., Niederacher D., Larbig D. Reliability and clinical application of fetal genotyping with two different fluorescent duplex polymerase chain reaction assays: three years' experience. Am J Obstet Gynecol. 180:1999;435-440.
88. Avent N. D. The rhesus blood group system: Insights from recent advances in molecular biology. Trans Med Revs. 13:1999;245-266.
89. Maaskant-van Wijk P. A., Faas B. H., de Ruiter J. A. Genotyping of RHD by multiplex polymerase chain reaction analysis of six RHD- specific exons. Transfusion. 38:1998;1015-1021.
90. Flegel W. A., Wagner F. F., Muuler R., Gassner C. Rh phenotyping prediction by DNA typing and its application to practice. Transfus Med. 8:1998;281-302.
91. Woodrow J. C., Clark C. A., Donohoe W. T. A. Mechanisms of Rh prophylaxis: An experimental study on specificity of immunosuppression. BMJ. 2:1975;57-59.
92. Karlsson M. C., Wernersson S., Diaz de Stahl T. Efficient IgG-mediated suppression of primary antibody responses in Fc-gamma receptor-deficient mice. Proc Natl Acad Sci USA. 96, 5:1999;2244-2249.
93. Prescribers' Journal. 31:1991;137-145.
94. Memorandum on haemolytic disease of the newborn, 1976 - addendum 1981. 1982;Department of Health and Social Security, London.
95. Contreras M. The prevention of Rh haemolytic disease of the fetus and newborn - General Background. Br J Obstet Gynaecol. 105:1998;7-10.
96. Robson S. C., Lee D., Urbaniak S. J. Anti-D immunoglobulin in RhD prophylaxis. Commentaries. Br J Obstet Gynaecol. 1998;105; 129-134.
97. Tovey, L. A. D. Haemolytic Disease of the Newborn and its Prevention. Marcela, Contreras, ABC of Transfusion. BMJ Publishing Group, 1992, 22, 25.
98. Haemolytic Disease of the Newborn. 1976;Department of Health and Social Security, London.
99. Bowman J. M., Pollock J. M. Rh isoimmunisation during pregnancy: antenatal prophylaxis. Can Med Assoc J. 118:1978;623-627.
100. Bowman J. M., Pollock J. M. Antenatal prophylaxis of Rh isoimmunisation: 28 week-gestation service program. Can Med Assoc J. 118:1978;627-630.
101. Tovey L. A.D., Townley A., Stevenson N. J. The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet. ii:1983;244-246.
102. Herman M., Kjellman H., Ljunggren C. Antenatal prophylaxis of Rh immunisation with 250 mcg of anti-D immunoglobulin. Acta Obstet Gynecol Scand (suppl), 124:1984;4-15.
103. Bowman J. M., Pollock J. M. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev. 1:1987;101-112.
104. Huchet J., Dallemagne S., Huchet C. The antepartum use of anti-D immunoglobulin in rhesus negative women. Parallel evaluation of fetal blood cells passing through the placenta. The results of a multicentre study carried out in the region of Paris. J Gynecol Obstet Biol Reprod (Paris). 16:1987;101-111.
105. Trolle B. Prenatal Rh-immune globulin prophylaxis with 300 mcg immune globulin anti-D in the 28th week of pregnancy. Acta Obstet Gynecol Scand. 68:1989;45-47.
106. Thornton J. G., Page C., Foote G. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. BMJ. 298:1989;1671-1673.
107. Lee D., Rawlinson V. Multicentre trial of antepartum low dose anti-D immunoglobulin. Transfus Med. 5:1995;15-19.
108. Urbaniak S. J. The Scientific Basis of Antenatal Prophylaxis. Br J Obstet Gynaecol, 105:1998;11-18.
109. Vick S., Cairns J., Urbaniak S. An economic evaluation of antenatal anti-D prophylaxis in Scotland. Health Economics. 5:1996;319-328.
110. Cairns J. A. Economics of Antenatal Prophylaxis. Br J Obstet Gynaecol. 105:1998;19-22.
111. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 39:1999;1160-1168.
112. Power J. P., Lawlor E., Davidson. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet. 346:1995;372-373.
113. Turner M. L., Ironside J. W. New-variant Creutzfeldt-Jacob disease: the risk of transmission by blood transfusion. Blood Revs. 12:1998;255-268.
114. Al-Mufti R., Howard C., Overton T. Detection of fetal messenger ribonuceic acid in maternal blood to determine fetal RhD status as a strategy for noninvasive prenatal diagnosis. Am J Obstet Gynecol. 179:1998;210-214.
115. Lo Y. M. D., Hjelm N. M., Fidler. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med. 339:1998;1734-1738.
116. Thompson K. H., Hughes-Jones N. C. Production and characterisation of monoclonal anti-Rh. Contreras Marcela. Blood Transfusion: The Impact of new Technologies. Bailliere Clinical Haematology Series, 1990;243-253 Bailliere, London.